AZD2796 / AstraZeneca - LARVOL DELTA

Single-Cell Transcriptomics Uncovers Cellular Dynamics and Potential Anti-Tumour Macrophage Repolarization in a Tri-Culture Model of the Tumour Microenvironment (ESMO-IO 2025) - "Macrophages are known to influence immune responses, and agents such as anti-LILRB2 (AZD2796) have been explored for their capacity to repolarise macrophages into anti-tumour phenotypes...The presence of fused macrophages suggests a specialized phagocytic function that merits further investigation. These findings highlight the dynamic interplay within the TME and support ongoing efforts toward macrophage-targeted immunomodulation in cancer therapy.Legal entity responsible for the study The authors."

Tumor microenvironment • Breast Cancer • Oncology • Solid Tumor • CD63 • CD8 • CSF1 • LAMP3

LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity. (PubMed, J Immunother Cancer) - "These findings support the potential of AZD2796 as an anti-cancer therapy, with the ability to synergize with T-cell-based therapeutics."

Journal • Oncology • Solid Tumor • CD34 • CD40LG • LILRB2

AZD2796, a myeloid checkpoint inhibitor targeting LILRB2 that promotes pro-inflammatory responses by macrophages and enhances T cell anti-tumor activity (SITC 2023) - "Conclusions AZD2796 is a high affinity anti-LILRB2 monoclonal antibody that promotes pro-inflammatory responses by macrophages and enhances anti-tumor activity of T cells. Our pre-clinical data support the potential of AZD2796 as an anti-cancer therapy with opportunities to combine with T-cell-based therapeutics."

Checkpoint inhibition • Lung Cancer • Melanoma • Oncology • Solid Tumor • CD40LG • TNFA